Recruiting Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). NCT06607692 Conditions Adrenal Cortex Diseases, Adrenal Cortex Neoplasms, Adrenal Gland Diseases, +57 more Locations HM Monteprincipe — Boadilla del Monte, Madrid, Spain View Trial Details
Enrolling by Invitation National Study of Adrenal Tumours NCT06870396 Conditions Adrenal Gland Diseases, Adrenal Gland Neoplasms, Adrenal Tumours, +13 more Locations Cambridge NHS — Cambridge, UK, United Kingdom View Trial Details
